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NOTES
Pharmaceutical Patents and TRIPS:
A Comparison of India and South Africa*
BY STEPHEN BARNES*"
I. INTRODUCTION
p atent protection is directly connected to the world's economy. The
international patent system has a powerful effect upon the indus-
tries and economies of individual nations. The international patent system
and individual domestic patent structures play a central role particularly in
the areas of science and technology. In several industries across the globe,
patent law heavily influences research, manufacturing, and marketing. By
extension, patent law influences price and access to products.
One of the complex issues involving patent law is that of pharmaceuti-
cal development. Pharmaceuticals are special products that have a profound
significance in people's lives. Especially in the modem era, with the AIDS
crisis growing year by year, the demand for life-saving medications is
extremely high. When compared with the interests of suffering patients, the
profits of a corporate patent-holder seem an insignificant and even vulgar
concern. The development of effective medicines, however, is an expensive
and time-consuming business that requires massive amounts of capital.
Without patent protection, pharmaceutical development would lose its
profitability and ultimately its momentum. Additionally, effective dis-
"This Note was originally written as a seminar paper for Professor Mary J.
Davis' Comparative Law Seminar.
"" J.D. expected 2003, University of Kentucky. The author wishes to dedicate
this Note to Barbara Dean Barnes (1940-2002), teacher, doctor, and beloved
mother. The author would like to thank Angela Elizabeth Minella for her constant
love and support, and would like to thank his family and friends. Last, and most
certainly least, the author wishes to thank Kurt Vonnegut, Jr., for teaching us that
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tribution of medicines at the local and personal level is an important
concern largely unrelated to patent protection. Thus, the issue is an
extremely complex one.
This Note focuses on the issue of pharmaceutical development in two
countries: India and South Africa. A recent intellectual property treaty, over
which the World Trade Organization ("WTO") has authority, has become
the focal point for disputes between these two countries and within the
international community. The intellectual property treaty, Trade-Related
Aspects of Intellectual Property ("TRIPS"),1 provides potent patent
protection, and, until recently, conflicted with certain Indian and South
African patent laws.
First, this Note discusses the history of medical research, the American
pharmaceutical industry, and the historical and philosophical underpinnings
of various patent laws.2 Second, this Note compares Indian and South
African patent laws in the context of the TRIPS drug disputes, including a
discussion of the history of each law, the philosophy upon which it is
based, and the relevance of the provisions to the issue of pharmaceuticals.3
A. Pharmaceutical Research
While new medicines are produced at an astounding rate, effective
medicines are a relatively recent phenomenon. "Less than two dozen
effective drugs were known before the year 1700."4 In a world with
pervasive superstition, lack of widespread communication, and no scientific
method, most medicines were worthless. "The few effective drugs that were
known were used alongside many other substances that were either
valueless or downright poisonous."5
Physicians prescribed various medicines without a full understanding
of their effects. In ancient Egypt, for example, baldness was treated with "a
mixture of writing ink and cerebrospinal fluid."6 Robert Boyle, a noted
'Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15,
1994 [hereinafter TRIPS], reprinted in THE RESULTS OF THE URUGUAY ROUND OF
MULTILATERAL TRADE NEGOTIATIONS-THE LEGAL TEXTS 6-19, 365-403 (GATT
Secretariat ed., 1994).
2 See discussion infra Part I.A.-C.
' See discussion infra Parts II, III.
4 HARRY F. DOWLING, MEDICINES FOR MAN: THE DEVELOPMENT, REGULATION,
AND USE OF PRESCRIPTION DRUGS 14 (1970) (These drugs included aloe, figs,
caster oil, alcohol, opium, quinine, iron, strychnine, and iodine. Several of these
early medicines were derived from plants and animals.).
5Id. at 15.
6id.
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seventeenth-century chemist, "treated his patients with powdered cow dung
for infection of the eyes."7 Other examples of subsequently discredited
medicines were "ants, earthworms, grasshoppers, the excrements of
pigeons, the tails of lizards, [and] the eyes of crayfish."8 Expressing his
disgust with nineteenth-century medical science, Justice Oliver Wendell
Holmes wrote that "if the whole materia medica, as now used, could be
sunk to the bottom of the sea, it would be all the better for mankind---and
all the worse for the fishes."9
During and after the Renaissance, however, science began developing
rapidly. In the eighteenth and nineteenth centuries, chemical compounds
were isolated, purified, and measured so that "the therapeutic properties of
[a] drug could be studied accurately and any adverse effects could be
clearly attributed to it."'" By the early twentieth century, chemists had
developed a method of "extracting from the natural product the portion
having the pharmacological effect."" Improved "chemical invention and
clinical observation"' 2 and the combination of drugs discovered in
"compounds [ ] that were effective in a larger group of diseases and caused
fewer adverse effects"' 3 were other significant Steps in the development of
modem pharmaceutical research.
This foundation led to the development of more sophisticated
techniques, including synthesizing chemicals found in nature and manipu-
lating the chemical composition of drugs.14 Modem pharmaceutical
research is well-organized, efficient, and prolific.
A massive multi-national drug industry, which devotes a great deal of
its energies to research, now exists. Government regulatory agencies and
sophisticated industry research departments work together to develop
medicines safely and rapidly. "Currently, the [American] pharmaceutical
industry has more than 1,000 medicines in development-either in human
clinical trials or at FDA awaiting approval."' 5 Each year, medicines are
developed, approved, and distributed at an increasing rate. "During the
7Id. at 16.
81d. at 24.
9 Id. at 17 (quoting OLIVER WENDELL HOLMES, MEDICAL ESSAYS (1891)).
IId. at 16-17.
"Id. at25.
1d. at 17.
1d. at 22.
141d. at 25.
'" PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, 2001-2002
ANNUAL REPORT * 1, at http://www.phrma.org/publications/publications/annual
report/2002/innovation.cfn [hereinafter PHRMA ANNUAL REPORT].
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1990s, the [American] industry developed 370 new medicines--up from
239 in the previous decade."' 6
More than most other industries, the pharmaceutical industry devotes
a great deal of its resources to research and development ("R&D"). "During
the past two decades, the [American] industry's percentage of sales
allocated to R&D has jumped from 11.9 percent in 1980 to 18.5 percent in
2001. This compares to an average of less than 4.0 percent for all U.S.
industries."'7 In the modem era, medicine can no longer be "sneeringly
referred to as the withered arm of science."' 18
B. What is the Justification for Patent Protection?
Drug innovation and intellectual property protections go hand-in-hand.
The prolific research by the pharmaceutical industry requires billions of
dollars of investment, and patent protections assure that drug companies
will earn the resulting profits. Theoretically, a country's patent system
"provides key incentives to inventive work and its related investment cost[ ]
by ensuring that the inventor derives certain economic benefits from his or
her work for a fixed period of time, generally 20 years."' 9 The patent
system requires a description of the compound to be patented, which in turn
allows the compound to be manipulated and improved upon-one of the
essential techniques of medicinal development. "[K]ey information on the
invention is made available to the public and to other researchers, thus
adding to the general body of accessible technical knowledge in the world.
... Medical researchers rely heavily on previous work in developing better
drugs to treat diseases."2 According to Abraham Lincoln, "[t]he patent
system added the fuel of interest to the fire of genius."21
A patent is a "publicly available document[ ]"22 that describes an
invention in terms "sufficiently full, clear, concise, and exact to enable any
person skilled in the art to which the invention pertains to be able to make
161d.
17Id.
18 DOWLING, supra note 4, at 17.
'" World Intellectual Property Organization (WIPO), Striking a Balance: Patents
and Access to Drugs and Health Care, at http://www.wipo.org/about-ip/en/studies/
publications/healthcare.htm (last visited Apr. 2, 2003).
20 Id.
21 HERBERT F. SCHWARTZ, PATENT LAW AND PRACTICE 3 (3d ed. 2001) (quoting
Abraham Lincoln, Speech in Springfield, Illinois (Feb. 5, 1859)).
22 Edmund W. Kitch, The Patent Policy Of Developing Countries, 13 UCLA
PAC. BASIN L.J. 166, 169 (1994).
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and use the invention."23 Patents give inventors the right to "exclude others
from making, using, offering for sale, or selling the patented invention...
for the life of the patent., 24 Thus, on the rare occasions that patents cover
profitable inventions, they can be extremely valuable to their holders. The
drafters of a 1791 French patent law took the position that "it would be a
violation of the rights of humanity in their very essence if an industrial
invention were not regarded as the property of its creator,"25 presumably
due to the personal value of the patent to its holder and the societal value
in innovation.
The relationship between patents and innovation has long been
apparent, and it is often argued that strong patent protection is a catalyst for
innovation. "As early as 500 B.C., the Greek colony of Sybaris granted
[patent-like] rights. 26 In Renaissance Italy, the general patent statute of the
Venetian Republic in 1474 included the following language:
We have among us people of great genius, apt to invent and discover
ingenious devices; and in view of the grandeur and virtue of our City,
more such people come to us every day from divers parts. Now, if
provision were made for the works and devices discovered by such
persons, so that others who may see them could not build them and take
the inventor's honor away, more people would then apply their genius,
would discover, and would build devices of great utility and benefit to our
Commonwealth.27
Statutory and constitutional language may include the idea that patents
"promote" innovation. According to the United States Constitution,
Congress may "promote the Progress of Science and useful Arts, by
23 SCHWARTZ, supra note 21, at 14 (citing 35 U.S.C. § 112, 1 (1988)). "For
an invention to be patentable, it must be (1) of patentable subject matter, (2) useful,
(3) new, and (4) nonobvious." Id. at 61.24Id. at 2-3.
23 A. Samuel Oddi, TRIPS-Natural Rights and a "Polite Form of Economic
Imperialism, "29 VAND. J. TRANSNAT'L L. 415,421 (1996) (citing 2 Lois & ACTES
DU GOVERNMENT (1790-9 1), reprinted in part and translated in Frank D. Prager, A
History of Intellectual Property From 1545-1787, 26 J. PAT. & TRADEMARK OFF.
SoC'Y 711, 756-57 (1944)).
26 SCHWARTZ, supra note 21, at 1.
27 Oddi, supra note 25, at 419 (quoting Giulio Mandich, Venetian Patents
(1450-1550), 30 J. PAT. & TRADEMARK OFF. SOC'Y 166, 176-77 (1948)
(translated by F.D. Prager from Giulio Mandich, Le Privative Industriali
Veneziane (1450-1550), 34 RIVOSTA Di DiRiTro COMMERCIALE 511 (1936))).
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securing for limited Times to ... Inventors the exclusive Right to their
respective... Discoveries."2 The fact that this provision was included in
the Constitution shows a strong belief of the drafters that scientific
development was closely related to patents and that science would prove
important to the young nation.
While modem international patent legislation is often criticized as
being influenced by wealthy innovators,2 9 it was societal interest rather than
the interest of the innovator that prompted the Founding Fathers to include
this provision in the Constitution. "The patent monopoly was not designed
to secure to the inventors ... natural rights in their discoveries. Rather it
was a reward, an inducement, to bring forth new knowledge."3
The theory that stronger patent laws promote innovation influences
domestic and international law. During the early 1980s, judicial decisions
and legislation helped make patents more valuable,3' including the creation
of the Federal Circuit in 1982, which, among other functions, is a national
patent court of appeals.32 The belief that strong, uniform patent protection
is a motivating factor for innovation has deeply influenced the United
States government and the international community.
C. TRIPS
Powerful members of the international community come together to
create uniform international standards for patent legislation. These
standards were codified in 1994 in the TRIPS33 Agreement of the General
28 U.S. CONST. art. I, § 8,'cl. 8.
29 See infra notes 36-37 and accompanying text.
3
1 Oddi,.supra note 25, at 420 (quoting Graham v. John Deere Co., 383 U.S. 1,
8-9 (1965), in which the United States Supreme Court described Thomas
Jefferson's philosophy of patents). Patents grant the holder the right to the
exclusive use of an invention, and Professor Oddi notes that "Jefferson and other
notable U.S. citizens abhorred monopolies." Id. at n. 14.
31 See SCHWARTZ, supra note 21, at 4-5. In support of his proposition that the
patent system was "buttressed" in the late 1970s and early 1980s, Professor
Schwartz cites a 1980 "reexamination statute" (35 U.S.C.A § § 301-307 (West 1984
& Supp. 2000)) that "allowed patent owners to strengthen their issued patents by
having the PTO reexamine them in light of certain types of 'prior art."' Id. at 5.
The judicial branch also played a role. Schwartz cites Diamond v. Chakrabarty,
447 U.S. 303 (1980) and Diamond v. Diehr, 450 U.S. 175 (1980), which
recognized microorganisms and computer programs, respectively, as within the
"broad scope of patentable subject matter." Id. at 5 & nn.25-26).
32 Id. at 5.
33 TRIPS, supra note 1.
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Agreement on Tariff and Trade ("GATT") treaty.34 TRIPS is the section of
GATT that contains international patent obligations, and provides an
extremely high standard of patent protection. 35 To join the WTO, a nation
must agree to become subject to the broad GATT treaty, which includes the
TRIPS patent provisions.
Different theorists give varying reasons for what they consider the
driving force behind the most recent treaty. Professor A. Samuel Oddi, an
authority on international patents, explained the adoption of TRIPS in the
following critical manner:
Industry groups (lobbyists) in developed countries, particularly in the
United States, found a receptive government ear to their plea that their
intellectual property was being "counterfeited," "pirated," "stolen," and
"infringed" to their detriment and to the detriment of intellectual property-
exporting countries by a generally bad lot in certain countries.
36
This criticism of TRIPS is common. Another more spirited criticism
included the following language: "[T]he TRIPS Agreement, in its current
form, acts as a vehicle for Western imperialism over developing countries
... [and, as administered by the WTO, an instrument] for forcing open
markets to United States corporations at any cost, including the destruction
of livelihoods, the environment, and human health."" Critics conclude that
the strong patent protection in TRIPS was enacted to benefit private
industry at the expense of poorer nations, rather than to promote innovation
and benefit society as a whole.
Another argument is that TRIPS is part of the natural and economically
sensible continuation of a post-World War II attempt to create a suitable
framework for the international economy. This argument holds that TRIPS
is part of the important process that included the adoption of GATT and the
WTO treaties. Many of the post-war world leaders considered the
breakdown of international trade during the Great Depression as a major
contributor to the instability that led to World War II, which was one
" General Agreement on Tariffs and Trade, Oct. 30, 1947, 61 Stat. A- 11,
T.I.A.S. 1700, 55 U.N.T.S. 194.
35 Matthew Kramer, Comment, The Bolar Amendment Abroad: Preserving the
Integrity ofAmerican Patents Overseas After the South African Medicines Act, 18
DICK. J. INT'L L. 553, 559 (2000).
36 Oddi, supra note 25, at 424.
37 Nadia Natasha Seeratan, Comment, The Negative Impact of Intellectual
Property Patent Rights On Developing Countries: An Examination of the Indian
Pharmaceutical Industry, 3 SCHOLAR 339, 347, 365 (2001).
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impetus for the establishment of GATT in 1947.3" GATT was a forerunner
to the WTO treaty and includes the TRIPS Agreement.39 Matthew Kramer,
a graduate of the Dickinson School of Law, describes the adoption of
TRIPS as one aspect of the gradual move towards economic globalization
and a step in a multi-national effort spanning half a century.4" "[T]he push
for more secure and stable international trading systems, and the emergence
of the hyper-connected international economy, have necessitated strict
intellectual property protections."'" Thus, this modem theory focuses on the
idea that strong patent protection is essential to a stable international
economy, but not necessarily because it promotes innovation.
The Director of the Intellectual Property and Investment Division of the
WTO, Adrian Otten, describes the philosophical basis for the TRIPS
Agreement as follows:
[N]egotiation of the TRIPS Agreement was prompted by the perception
that inadequate standards of protection and ineffective enforcement of
intellectual property rights were often unfairly depriving the holders of
such rights of the benefits of their creativity and inventiveness, and, as a
result, prejudicing the legitimate commercial interests of their respective
countries.... [It was perceived] that a major agreement on intellectual
property was a necessary component . . . to the maintenance and
strengthening of the multilateral trading system as a whole.42
There is probably some element of truth in each of the various descriptions
of TRIPS.
II. INDIA AND SOUTH AFRICA
Factors other than a powerful drug industry and the development of the
international community have influenced patent law in India and South
Africa. Protectionism has shaped patent legislation in India.43 South Africa,
on the other hand, altered its patent legislation in response to the cata-
strophic public health situation caused by AIDS.44 This Note discusses
these two countries in detail below.45
38 Kramer, supra note 35, at 557.
39 Id. at 556-57.
40 See id. at 556-60.
41 Id. at 557.
42 Adrian Otten & Hannu Wager, Compliance With TRIPS: The Emerging
World View, 29 VAND. J. TRANSNAT'L L. 391, 393 (1996).
43 See discussion infra Part II.A-C.
44 See discussion infra Part II.D-E.
4' These two countries are discussed in detail in this Section.
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The strong patent protection of TRIPS has brought the United States
into conflict with Indian and South African patent laws. Considering the
philosophical underpinnings of the different legal systems leads to a better
understanding of why each country adopted particular policies. The United
States, as discussed above, strongly believes that patents promote innova-
tion. Conflicting interpretations exist as to what prompted the adoption of
the TRIPS Agreement, but fears about "pirating" inventions, lobbying by
powerful private industry, and a desire to maintain a stable international
economic framework may have been part of the equation. Concerns about
the future of India's pharmaceutical industry and domestic health concerns
prompted India to adopt weak patent laws, especially with respect to
pharmaceuticals. South Africa's disastrous public health situation led to the
passage of its controversial patent legislation.
A. India's History and Patent System
This section will discuss the historical and philosophical bases for
India's weaker patent model, as well as some of its more relevant provi-
sions. India engages in what is known as free-riding, which is the practice
of disregarding a foreign patent and manufacturing the product that the
patent protects.46 "[S]ome countries may decide that they can win by free-
riding on the patented technology developed elsewhere without substan-
tially slowing the march of technological development., 47 For instance, an
American pharmaceutical company may research, develop, test, and after
an extensive testing and approval process, manufacture a certain drug. This
process may span several years and cost the company millions of dollars.
Finally, the company must apply for a patent in each country in which it
wishes to market the product. The free-riding occurs when a foreign
company takes the product and manufactures it, disregarding the patent
protection afforded the American company. An Indian company will
manufacture products, particularly pharmaceutical products, that have been
developed elsewhere without concern for whether the products are
patented.
India, an English Colony until 1947, had pre-independence patent laws
based upon those of England.48 India was under British rule for over 100
4 Martin J. Adelman & Sonia Baldia, Prospects and Limits of the Patent
Provision in the TRIPS Agreement: The Case of India, 29 VAND. J. TRANSNAT'L
L. 507 (1996).
471d. at 510.
48 See id. at 518.
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years before its independence. 9 Before that, the Indian subcontinent was
home to a collection of varied cultures and tribes with only fragile
cohesion. It was the independence movement that brought modem-day
India into existence. At the time of India's independence, the Indian Patents
and Design Act of 1911 was the existing patent law.5" The newly independ-
ent nation wanted to revamp its British patent system to make it more
Indian and more in line with national goals.5 The first Prime Minister of
India, Jawaharlal Nehru, was concerned that foreign companies would
control the Indian economy. In 1948 and again in 1957, two government
committees were formed to evaluate the patent system. The reports of these
two committees, the Tek Chand Committee in 1948 and the Ayyangar
Committee in 1957, led to an overhaul of Indian patent law.53
The committees found that between eighty and ninety percent of the
Indian patents were held by foreigners and more than ninety percent of
them were not worked [i.e. used by manufacturers] in India. The
committees asserted that the system was being exploited by foreigners to
achieve monopolistic control over the market. In regard to vital industries
like food, chemicals, and pharmaceuticals, the data for patents was similar
for the period 1947 through 1957. Medicines were arguably unaffordable
to the general populace, and the drug-price index was rising .... 54
... In the early 1940s and 1950s, ninety percent of the [Indian] drug
market was under the control of foreign companies, and the country was
totally dependent on imports for both bulk drugs (the active ingredients)
and formulations (the medicines made from bulk drugs). As a result,
Indian drug prices were then among the highest in the world.55
After extensive debate and delay, the Indian parliament passed the
Patent Act of 1970,56 which, ironically, is "a copy of the English Patent Act
of 1949,,,57 except that it provides much less patent protection.
'9 David K. Tomar, A Look into the WTO Pharmaceutical Patent Dispute
Between the United States and India, 17 Wis. INT'L L.J. 579, 580 (1999).
5' Adelman & Baldia, supra note 46, at 518.
5'Id.
52 Tomar, supra note 49, at 581.
5 Adelman & Baldia, supra note 46, at 518.
54Id. (emphasis added).
51 Id. at 526.
16Id. at 518.
571d. at 518-19.
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The objectives of the Act included the following: "[T]o encourage
inventions and to secure that [they] are worked in India,. . .[to ensure that]
they are not granted merely to enable patentees to enjoy a monopoly for the
importation of the patented article,... [and to prioritize the] public interest
over the private interest of the inventor."58 The objectives of the Act as
listed in its text are unapologetically protectionist, which is not surprising
in view of the Committee's findings. Modem India had set a goal to free
itself from foreign monopolies and establish strong domestic industries.
Indian patent law is particularly weak for certain inventions. While
medicines and drugs may not be patented, "process claims covering
methods of their manufacture are patentable."59 These patents expire much
more rapidly than those of other countries. "The term for inventions
involving the method or process of the manufacture of a substance to be
used as a food, medicine, or drug is five years from the date of sealing or
seven years from the filing date of the complete specification, whichever
is shorter."'6 The minimum term under the TRIPS Agreement, however, is
twenty years.6 '
The term "sealing" refers to the grant of a patent upon the applicant's
request after termination of the examination and opposition procedures.62
Opposition procedures may take a great deal of time. A "complete
specification" is included in the original application for the patent.63 "Its
claims define the boundaries of the patentee's property rights. The
complete specification should fully describe the invention and the method
by which it is to be carried out and disclose the best mode of performing
the invention known to the applicant."'
In other words, five years from the grant of a medicine "process" patent
which has overcome opposition and passed examination, it will expire.
Seven years from the time of application for one of these patents, it will
expire. "[I]t is possible that a patent which is opposed will expire before the
opposition is concluded. Hence, for processes that come within this special
definition, patent protection is plainly minimal" 65 when compared to that
of other countries. As noted above, TRIPS requires member countries to
58 Id. at 519 (citing The Patents Act, No. 39, § 83(a) (1970) (India) [hereinafter
India Patents Act]).
59 Id. at 520 (citing India Patents Act, § 5(a), (b)).
60 Id. at 523 (citing India Patents Act, §§ 53(l)(a), 45).
61 TRIPS, supra note 1, art. 33.
62 Adelman & Baldia, supra note 46, at 523 n.77.
63 Id. at 520.
64 Id. at 521 (citing India Patents Act § 10(4)(a), (b)).
65Id. at 523.
2002-20031
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establish a minimum of twenty years of patent protection.66 India, a
signatory to GATT, "has resisted altering its weak patent law system,
thereby violating the agreement it so recently signed."67
Another weak aspect of the Indian patent system is its licensing system.
The Indian "government has required that all private manufacturing
enterprises be licensed."68 All foreign technology licenses must obtain
approval from the government, and their terms are also very short.6 9 Once
a license agreement expires, the patent holder has neither patent protection
nor any right to collect royalties.7"
One of the most potent protectionist tools in the Indian patent system
is its compulsory licensing system.
"Compulsory licensing" allows a nation to select a firm in their
nation to make the drugs and sell them at... [low] cost. The patent holder
is given a small royalty....
Before a nation may use compulsory licensing, the nation must
attempt to get a voluntary license for the drug. The nation must also make
payments for the use of the patented drug, and its decision to use the drug
must be subject to some form of independent or judicial review.
71
In any patent system, compulsory licenses serve the important purpose
of forcing greedy patent holders to allow production of their products at
reasonable prices. If a patent holder does not attempt to work the patent in
the relevant country, a compulsory license will force them to do so. Unless
they are used rarely, however, compulsory licenses can significantly erode
patent protection. Under the TRIPS Agreement, for example, "[c]om-
pulsory licensing and government use without the authorization of the right
holder are allowed, but are made subject to fifteen conditions aimed at
protecting the legitimate interests of the right holder."72 Compared with
66 See supra note 61 and accompanying text.
67 Tomar, supra note 49, at 579.
68 Le-Nhung McLeland & J. Herbert O'Toole, Patent Systems in Less Devel-
oped Countries: The Cases of India and the Andean Pact Countries, 2 J.L. &
TECH. 229, 236 (1987).
69 id.
70 Id. at 237.
71 Herman Reinhold, Patients v. Patents, No. 4 INTELL. PROP. L. NEWSL.
(A.B.A. Publ'n), Summer, 2001, at 4.
72 Otten & Wager, supra note 42, at 401 (citing TRIPS, art. 31). Article 31
contains the following requirements:
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developed nations, the Indian compulsory licensing scheme is much more
likely to be used.
In India, the government grants compulsory licenses for patents if the
patents have not been worked by the patentee or are not available to the
people of India at a low enough cost.7 3 The large amount of discretion in
the decisions makes the patent application process especially susceptible
to the corruption pervading the Indian bureaucracy. Under the compulsory
licensing rules, patents on food and medicines may be overridden three
years from the time of sealing, whether or not the patent holder has
attempted to "work" the invention.74 Thus, even when the patent holder
makes a good faith effort to work the drug locally, and even if the
technology is a type that can be patented, "the patents are only effective for
a period of three years from sealing."75 India's compulsory licensing system
(a) authorization for compulsory licensing must be considered on the
merits;
(b) the licensee must have attempted to obtain authorization from the
patent holder on reasonable commercial terms and that such efforts
remained unsuccessful after a reasonable period of time had passed;
(c) the scope and duration of the compulsory license shall be limited to
the purpose for which it was originally authorized;
(d) the use of the compulsory license shall not be exclusive;
(e) the use shall not be assignable;
(f) the compulsory license shall be authorized predominantly for the use
of the domestic market of the Member authorizing the compulsory
license;
(g) authorization for the compulsory license shall cease when the circum-
stances that necessitated its implementation no longer exist;
(h) the patent holder shall receive appropriate compensation for the use
of the patent and such compensation shall be determined by taking into
account the economic value of the license;
(i) the legal validity of any compulsory license scheme shall be subject to
judicial review;
(j) the determination of appropriate compensation to be paid to the patent
holder shall be subject to judicial review;
(k) anti-competitive practices by the patent holder shall be taken into con-
sideration; and
(1) additional conditions shall apply where use is authorized to exploit the
second patent which cannot be exploited without infringing another
patent.
13 Adelman & Baldia, supra note 46, at 524 (citing India Patents Act § 84(1)).
7 McLeland & O'Toole, supra note 68, at 235.
7 Adelman & Baldia, supra note 46, at 524 (citing India Patents Act §
87(l)(a)).
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is clear evidence of the protectionist philosophy underlying its patent
system. After the passage of the 1970 Act,76 foreign patent applications
declined significantly. "[I]n the area of chemical processes, drugs, and food
articles, the statistics show that the world at large believes India provides
little patent protection."77
B. The Indian Pharmaceutical Industry
India's protectionist patent system has shown remarkable results.
Although India was totally dependent on foreign companies for drugs in
1947,78 it has a powerful independent pharmaceutical industry today.79
Weak patent laws allowed India to quickly enter into pharmaceutical
markets, both domestic and foreign, by allowing Indian-owned pharma-
ceutical companies to copy existing pharmaceuticals cheaply without the
expenditures of time and money that foreign pharmaceutical companies
spent on research and development. Also, Indian-owned pharmaceutical
companies feared neither legal infringement against pharmaceutical
developers nor the accompanying litigation expenses. Thus, by building
up Indian-owned pharmaceutical companies, India was able to reverse the
earlier trend and prevent large foreign multinational corporations from
dominating India's pharmaceutical sector, giving India autonomy which
affected both India's economic and political sectors.80
In 1947, Indian drug prices were among the highest in the world." At
the time of independence, Indian pharmaceutical companies did little more
than process ingredients imported from other companies. Now, however,
the reverse is true. As of the 1990s, "Indian companies control[led] seventy
percent of the domestic formulations market and eighty-five percent of the
bulk drugs market."82 At least in the area of drug production, Nehru's
concern about Indian industry dependence on foreign nations has been
avoided.
Not only is the Indian drug industry free from foreign domination with
respect to domestic markets, it is also a formidable international competi-
16 The Patents Act, 1970, No. 39 (India).
7 McLeland & O'Toole, supra note 68, at 237.
78 See supra notes 54-55 and accompanying text.
79 See infra note 82 and accompanying text.
80 Tomar, supra note 49, at 582.
8 Adelman & Baldia, supra note 46, at 526.
2Id. at 527.
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tor. Use of generic drugs is now common in the West, and "Indian
companies compete in the international race to exploit the huge market for
generic drugs."83 Compared to the weak, dependent industry of the late
1940s, the modem drug industry is almost unrecognizable. "Indian industry
has emerged as a world leader in the production of bulk drugs[, and]...
India has become a net exporter of drugs and has earned a considerable
reputation in the international market as a dependable bulk drug manufac-
turer. 8 4
This success was achieved, in large part, through the protectionist
patent legislation described above." In view of India's history as a
subservient colony, fears about foreign domination must have been
particularly compelling. It is not clear, however, that this justification is
acceptable fifty years after independence. In view of the fact that the Indian
drug industry is now a powerful international competitor, it seems
especially inappropriate to argue that there is imminent danger of foreign
domination.
C. Does Public Health Justify India's Weak Patent System?
There is no health concern to justify India's weak patent protection.
The health problems that Indian citizens face are unrelated to patent laws.
It is important to note that India's AIDS crisis, while serious, is not as
catastrophic as that of South Africa where a similar protectionist patent
system was in place. The adult rate of HIV/AIDS infection in India is 0.8%,
which is only slightly higher than the 0.6% rate in the United States. Such
a comparison is misleading, however, because India has a total population
of over 1 billion people. 6 The author does not wish to underemphasize the
83 Id. at 525.
14 Id. at 525-26.
85 See supra notes 59-77 and accompanying text.
86 See UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC 2002,190, 194,
198, at http//:www.unaids.org/barcelona/presskit/barcelona%20report/table.html
[hereinafter UNAIDS REPORT] (HIV/AIDS statistics are from this publication's
detailed "Table of Country-Specific HIV/AIDS Estimates and Data" section. These
estimates indicate that roughly 3.97 million people in India are living with AIDS,
which means India has the second highest amount of HIV infected people in the
world after South Africa. Id. at 194. Without discounting the seriousness of the
Indian epidemic, however, the author wishes to clarify the difference between
South Africa's epidemic and India's epidemic. Fewer than 1% of Indian adults
have HIV/AIDS, compared to about twenty percent of South African adults. Id. at
190, 194.).
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crucial importance of an HIV or AIDS epidemic in any region, but it is
important to realize that as horrible as India's epidemic is, it is simply not
on the scale of South Africa's. Thus, a national health issue as a justifica-
tion for free-riding is now largely economic and not founded on imperial-
ism or public health concerns.
In fact, one negative effect upon Indians caused by the free-riding
system is that the drug industry does not have an adequate research sector.
Because the weak patent system allowed the industry to take the inventions
of others, the industry devoted very little energy to developing its own
drugs. "[S]cientific research in India, mainly a government-run activity, has
been conducted under a few governmental or quasi-governmental
agencies" 87 which have been ineffective at developing new drugs. "Indian-
owned companies typically spend 1% of sales on R&D, compared to an
average of 15% by Western pharmaceutical companies."88 The common
sight of Indian scientists at American universities is misleading for two
reasons. First, "a large percentage of Indian scientists are engaged in
teaching and academic research and not industrial research." 9 Second,
many of the Indians who study in Western countries are lured by the
lucrative job opportunities and wealthy lifestyle and do not go back to
India.9" This lack of research capability is attributable, in part, to the patent
system.
Additionally, India has its own health concerns which deserve attention
and focused research. Drug companies in the West have no incentive to
develop treatments for many of the health problems that affect India.
Diseases like malaria and leprosy are not major concerns in the West, so
pharmaceutical companies lack an incentive to research possible cures.
"The technological needs of [India] are not the same as the technological
needs of a developed country."'" If a Western drug company does not
invent a treatment, Indian companies, while adept at copying, will not have
the capability to invent the drugs.92 Thus, not only may the Indian patent
system be justified on the basis of public health concerns, its stunting effect
on the Indian pharmaceutical industry's research capability has a negative
impact on Indian public health.
87 Adelman & Baldia, supra note 46, at 528.
8 8 Tomar, supra note 49, at 583; see also PHRMA ANNUAL REPORT, supra note
15.
89 McLeland & O'Toole, supra note 68, at 238.
90 Id.
91 Kitch, supra note 22, at 176.
92 Adelman & Baldia, supra note 46, at 511.
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Recently, in response to TRIPS, as well as to disputes with the United
States and the WTO, there has been a movement towards amending Indian
patent laws and creating research capabilities. On March 26, 1999, the
Indian government adopted the Patents Amendment Act of 1999, bringing
it into compliance with recommendations by the WTO. 93 These amend-
ments include provisions aimed specifically at "the reception of [foreign]
patents for pharmaceuticals." 94 Additionally, Indian "pharmaceutical
companies [have begun] trying to build technology muscle. A prime
example is Ranbaxy Lab, Inc... [which] signed a $90 million joint venture
with Eli Lilly & Co. to collaborate for drug research and development."95
Within ten to twenty years, the Indian drug industry and patent system
could be distinctively different from the way it is today. It may be that
India, recognizing the problems with its patent system, is attempting to
modernize and join the developed world.
D. South Africa's History and Patent System
South Africa had a patent system that was similar in many respects to
the pre-1999 Indian system. The philosophy underlying the South African
system is much different, however. While India structured its patent system
in an attempt to free itself from foreign economic control and later
maintained the system to bolster its pharmaceutical industry, South Africa
altered its patent system for public health reasons.
Like India, South Africa was under British Rule until the mid-twentieth
century. South Africa gained partial independence from England in 1910
and complete independence in 1932.96 Unlike the situation in India,
however, South African independence from Britain did not end racial
oppression. Africans have been dominated in South Africa from 1658,
when slaves were first imported into the new Dutch colony, until 1993
when Apartheid was abolished.97
The period between independence from Britain and the abolition of
Apartheid was marked by some particularly nasty legislation that kept
" Tomar, supra note 49, at 590.
94 Id.
" Adelman & Baldia, supra note 46, at 528. But see Jean-Francois Tremblay,
C&EN Talks with an Indian Iconoclast, CHEMICAL AND ENGINEERING NEWS, May
6, 2002, at 19 (discussing India's Chipla company, which sends AIDS medications
to Africa for dramatically less than Western drug companies).
96 See Emily Bourdeaux Smith, South Africa's Land Reform Policy and Inter-
national Human Rights Law, 19 WIS. INT'L L.J. 267, 269 (2001).
" See id.
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blacks from owning land, created numerous criminal offenses directed only
at blacks, and consolidated the power of the white minority.98 The "Three
Pillars of Apartheid," the Blacks Land Act 27 of 1913, the Blacks (Urban
Areas) Act 21 of 1923, and the Black Administration Act 38 of 1927
resulted in the "complete subjugation of blacks in South Africa."99 These
laws allowed the government to relocate individuals and even entire tribes
without compensation, limit the areas in which blacks could live and work,
alter tribal groups, and keep blacks from owning land.' The "legislation
created and thereafter sustained 'another world' wherein black persons
have been forced to live, work and raise their families under rules and
conditions which do not apply to other races in South Africa."'' ° For
example, Section 5 of the Black Administration Act 38 of 1927 gave the
Governor-General (i.e., the State President) the power to "divide existing
tribes into one or more parts, or amalgamate tribes or parts of tribes into
one tribe, or constitute a new tribe... [and] order the removal of any tribe
or portion thereof or any Native from any place to any other place within
the Union."'0 2 Blacks in South Africa were the most abject of second-class
citizens.
As a partial attempt to redistribute the stolen land, two new constitu-
tions have been enacted since the abolition of Apartheid: the 1993 interim
constitution and the 1996 final constitution.'0 3 One year after the adoption
of the final constitution, the patent legislation addressed in this Note was
passed. The patent legislation came on the heels of the newly drafted
constitutions, which themselves came immediately after the liberation from
Apartheid. It is important to be clear that public health, not economic
independence as it had been in India, was the impetus behind the passage
of the law.
E. The South African AIDS Crisis
One-fifth of the adult population in South Africa is infected with
HIV.'°4 Of a total population of thirty-nine million people, five million have
98 See Judge Justice Moloto, South African Legal Reform After April 1994, 26
N.C. J. INT'L L. & COM. REG. 653, 653-64 (2001).
99 Id. at 655.
100 Id.
ol Id. at 656.
'o2 Id. at 655 (citing Black Administration Act 38 of 1927, § 5(1), 6 BSRSA pt.
28 (2000)).
103 See id. at 664-68. S. AFR. CONST. (1993); S. AFR. CONST. (1996).
'04 UNAIDS REPORT, supra note 86, at 190.
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HIV.' Two hundred and fifty thousand of those infected are children. °6
"[Former] U.S. Surgeon General David Sacher has compared the current
African AIDS crisis to the Black Death that swept Europe five hundred
years ago."'0 7 South Africa's total HIV-infected population is the highest
in the world, and its percentage of adult HIV infection is the seventh
highest in the world, behind Botswana, Zimbabwe, Swaziland, Lesotho,
Namibia, and Zambia. 8 Lesotho and Swaziland are landlocked inside
South Africa, while Botswana, Zimbabwe, and Namibia share borders with
South Africa. The average percentage of adults infected with HIV in sub-
Saharan African countries is 9%, compared with 1.2% world-wide.0 9 Sub-
Saharan Africa in general, and particularly the southern tip of Africa, are
being devastated by AIDS.
In addition to the dramatically high numbers of HIV-infected South
Africans, the passage of the 1997 patent law attributed to South Africa's
poverty and inability to afford high-priced AIDS medicines from the West.
Although AIDS is an incurable disease, modem research has shown that
life may be prolonged by various medicinal therapies and that certain
treatments may also prevent transmission from mother to the fetus
altogether.' O "This treatment plan has reduced AIDS-related mortality by
over seventy percent in developed countries.""' Drugs that are neither
expensive nor difficult to manufacture "such as Retrovir, which can halt the
105 Id.
106 ld.
'07 Kramer, supra note 35, at 565 (quoting Africa Policy Information Center,
AIDS Drug Policy, AFRICA NEWS SERVICE, Sept. 7, 1999, available at 1999 WL
25944377).
'0' UNAIDS REPORT, supra note 86, at 190. The adult infection rates as of the
end of 2001 are as follows: Botswana: 38.8%, with 330,000 total infected adults
and children of a population of 1.5 million; Zimbabwe: 33.7%, with 2,300,000 total
infected adults and children of a population of 12.8 million; Swaziland: 33.4%,
with 170,000 total infected adults and children of a population of 938 thousand;
Lesotho: 31%, with 360,000 total infected adults and children of a population of
2 million; Namibia: 22.5%, with 230,000 total infected adults and children of a
population of 1.7 million; and Zambia: 21.5%, with 1,200,000 total infected adults
and children of a population of 10.6 million. Id.
109 Id.
"0 Mary K. Schug, Promoting Access to HIV/AIDS Pharmaceuticals in Sub-
Saharan Africa Within the Framework ofInternational Intellectual Property Law,
19 LAW & INEQ. 229, 235 (2001).
"I Id.
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transmission of AIDS from mothers to their unborn children, ' are very
expensive. The famous "triple-drug cocktail," which "includes two
nucleoside analogs and a protease inhibitor," is fantastically expensive,
even by American, standards." 3 "In 1992, seven AIDS treatment drugs
ranged in monthly price from $160 to $1,740, with yearly costs of $1,920
to $20,882."' "4 Although the prices have dropped,' these drugs are simply
out of reach for the people of South Africa. According to The World
Almanac, the South African Per Capita Gross Domestic Product was
$5,400 in 1999.116 Regardless of which is more accurate, it is clear that the
average South African could never afford AIDS medications at the prices
quoted above.
In 1997, the South African Parliament, recognizing the public health
catastrophe on its hands, passed the Medicines and Related Substances
Control Act, Act No. 90 of 1997."' "Included in this bill, specifically
[sections 15(c) and 22(c)], were provisions for parallel importing,
compulsory licensing, and a clause that overrules patent rights that prevent
South African companies from developing local versions of effective
treatments.""' As explained above, "compulsory licensing" is the practice
where a nation picks a domestic company to make the drug protected by a
foreign patent and then sells the drug for less than the patent holder would
charge." 9 "'Parallel importation' is reselling goods that were first sold in
another country. A nation would buy the drugs on the world market
wherever they are cheapest, and then import them for its own people."'
' 20
112 Kramer, supra note 35, at 565 (AZT stands for "azidothymidine" which is
actually an older name. It is now also called "RETROVIR," which is a brand name
for the chemical drug "zidovudine." THOMPSON PDR, 2003 PHYSICIANS' DESK
REFERENCE 1625 (57th ed. 2003)).
113 Reinhold, supra note 71, at 4.
114Id.
"I See UNAIDS FACT SHEET: ACCELERATING ACCESS TO TREATMENT AND
CARE (2002), at http//:www.w3.unaids.org/en/media/fact+sheets.asp. "In early
2000, the price of Highly Active Antiretroviral Therapy (HAART, also referred to
as triple therapy) for one patient for a year was US $1 0,000-US $12,000. By the
end of 2000, prices had dropped to US $500-US $800 per person per year for first-
line antiretroviral treatment in low-and middle-income countries. By December
2001, certain combinations of medicines cost US $350 per person per year." Id.
"' Kramer, supra note 35, at 565.
'19 See supra note 71 and accompanying text.
20 Reinhold, supra note 71, at 4.
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The Minister of Health in his individual discretion may use these tools
to override patent protections. "Specifically, [section 22(c) of] the amend-
ment grants the Minister of Health the power to allow for compulsory
licensing, provided the drug was initially marketed by the patentee or with
the patentee's consent and the drug does not have other expressed restric-
tions.
' 121
The minister [of Health] may prescribe conditions for the supply of
more affordable medicines ... so as to protect the health of the public,
and... may
[allow the importation of a medicine] which is imported by a person other
than the person who is the holder of the [patent].
[T]he council may ... issue ... a license to manufacture or act as a
wholesaler of or distribute ... such medicine or medicinal device.'
22
This Act is similar to the compulsory licensing scheme of the Indian Patent
Act of 1970.123 India and South Africa have implemented the tools of
compulsory licensing and weak patent protection for two different ends.
The international community, led by the United States, was infuriated
by the amendments. "Forty major drug companies sued, countering the...
Act in an attempt to protect pharmaceutical patent rights and corporate
profits. The United States [government] added more fuel to the fire and
waged an aggressive campaign to reverse the South African law.' ' 124 It is
unclear whether the law was in violation of TRIPS or not, because, as noted
above, TRIPS allows compulsory licensing under certain circumstances. 1
25
121 Rosalyn S. Park, The International Drug Industry: What the Future Holds
for South Africa's HIV/AIDS Patients, 11 MINN. J. GLOBAL TRADE 125, 136
(2002).
122 Medicines and Related Substances Control Amendment Act of 1997, Act
No. 90, §§ 15(c), 22(c) (BSRSA 1997).
123 See supra notes 73-77 and accompanying text.
124 Bess-Carolina Dolmo, Note, Examining Global Access to Essential Phar-
maceuticals in the Face of Patent Protection Rights: The South African Example,
7 BUFF. HUM. RTS. L. REv. 137, 138 (2001).
125 See supra note 72 and accompanying text; see also TRIPS, supra note 1, art.
31; see also Naomi A. Bass, Implications of the TRIPSAgreement for Developing
Countries: Pharmaceutical Patent Laws in Brazil and South Africa in the 21st
Century, 34 GEO. WASH. INT'L L. REv. 191, 199 (2002) (citing the TRIPS art. 31
conditions that must be achieved before a signatory nation may grant compulsory
licenses).
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The United States chose not to contest the law using the WTO mediation
process as it had in the case of the Indian Patent Act, perhaps because it
feared that the WTO mediators would find that South African law was not
in violation of TRIPS. 26 This issue remains unsettled.
Regardless of whether the South African law conflicted with TRIPS,
the dispute resulted in both sides backing away from the issue. The drug
companies withdrew their suit in April 2001, and the South African
Parliament passed the "South African Medicines and Medical Devices
Regulated Authority Act (SAMMDRA), which rescinded the Medicines
and Related Substances Amendment Act and the amendment."1 27 South
Africa has not attempted to grant compulsory licenses, and the international
community has lifted its pressure.
The South African parliament saw reforming its patent laws as the
solution to the AIDS crisis. Even if South Africa were to have access to the
drugs it seeks, it is doubtful that the people would receive them. "South
Africa does not have the infrastructure to effectively provide the drugs
now." '' 2 Treatment of AIDS is a complex, expensive, and long-term
process. Patents on AIDS medications are only a minor part of the health
crisis. A report prepared for the World Intellectual Property Organization
("WIPO") found that the necessary medical infrastructure will be costly to
develop, and foreign assistance is currently inadequate.' 29 The report also
provided that
•.. [T]he intellectual property rights of pharmaceutical companies
and the TRIPS agreement are not, in themselves, impediments to the
availability ofHIV/AIDS therapies in sub-Saharan Africa; and it is clearly
incorrect to assume that without restrictions imposed by the WTO through
TRIPS and without patents, HIV/AIDS patients would have access to
drugs crucial to their survival.
1 30
It is doubtful that even if South Africa had attempted to implement its
patent law it would have significantly helped the AIDS crisis.
126 See Dolmo, supra note 124, at 146 (claiming that former Vice President
Gore and other United States officials believed that the South African law was not
in violation of the TRIPS Agreement).
127 Park, supra note 121, at 137.
128 Reinhold, supra note 71, at 5.
129 The Intellectual Property Institute, Patent Protection and Access to HIVI
AIDS Pharmaceuticals in Sub-Saharan Africa (2000), at http://www.wipo.int/about
-ip/en/pdf/iipLhiv.pdf (last visited Apr. 2, 2003) (Report prepared for the World
Intellectual Property Organization (WIPO)).
'30Id. at 54.
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The medical community has not been convinced that strong patent laws
have exacerbated the African AIDS crisis, or that patent laws have been the
main impediment to drug access. A 2001 study published in the Journal of
the American Medical Association disclosed the following findings:
[It appears that] patents and patent law are not a major barrier to
treatment access in and of themselves. We conclude that a variety of de
facto barriers are more responsible for impeding access to antiretroviral
treatment, including but not limited to the poverty of African countries,
the high cost of antiretroviral treatment, national regulatory requirements
for medicines, tariffs and sales taxes, and, above all, a lack of sufficient
international financial aid to fund antiretroviral treatment.
131
Clearly, the West has a duty to attack the African AIDS crisis and must do
so soon. Several factors must be addressed, including funding, medical
infrastructure, education, and, of course, drug patents. It is also clear,
however, that blaming pharmaceutical companies and patent laws for the
AIDS crisis is excessively simplistic.
III. COMPARISONS
The histories of the United States, Western Europe, India, and South
Africa are all related to their modem patent laws. In the West, governments
have long understood the important connections between scientific research
and patent laws, as well as the powerful economic effects of patent laws.
The Indian government, with its goal of freedom from foreign control,
understood that weak patent laws could build up its economy. The South
African government, busy remedying the effects of Apartheid, had a major
epidemic on its hands and saw weak patent laws as the solution for its
troubles. The WTO looks to strong patent laws as a means to the goal of an
efficient and stable international economy.
Socially and culturally, the parties at issue here are very different.
While it is always difficult to make generalizations about hundreds of
millions of people, there are certain common themes relevant to this topic.
Western nations reap the benefits of strong patent laws through the
development of numerous medicines. Additionally, efficient medical
infrastructures make new medicines available to ordinary citizens, and
quality medical care is a realistic expectation for a large percentage of
131 Amir Attaran & Lee Gillespie-White, Do Patents For Antiretroviral Drugs
Constrain Access To AIDS Treatment In Africa?, 286 JAMA 1886 (2001).
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Western people. It is the West that determines the course of the interna-
tional community, and strong patent law is seen as another way to secure
the prosperity of the global economy.
In India, the foreign domination of the two previous generations must
be fresh in the minds of many people. Weak patent laws have been essential
to the Indian economy for many years. Because it is a nation with many
poor people, any threat to the Indian economy must seem severe.
South Africa, with its horrendous AIDS crisis, has a terrified popula-
tion. It is likely that every person in South Africa has been affected by the
epidemic in some way. It is easy to see how the national and regional AIDS
panic influenced the South African legislature into passing its weak patent
legislation.
The reasons underlying Indian and South African refusal to implement
strong patent protection, while superficially appealing, appear unsatisfac-
tory. India, with its massive population, powerful economy, and competi-
tive drug industry, is not at risk of foreign control. South Africa's struggle
with AIDS can only be a success through a Herculean effort, which
includes improving its medical infrastructure and receiving substantial help
from the rest of the world. Access to AIDS drugs is only part of the
solution.
As the economy of the world becomes more interconnected, treaties
like TRIPS will become increasingly important. As time passes and the
benefits of compliance become apparent, resistance by countries such as
India and South Africa may decrease.
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